Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Intermediate Risk Prostate Cancer.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2019
Price : $35 *
At a glance
- Drugs Padeliporfin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Steba Biotech
- 23 Dec 2019 Planned End Date changed from 15 Dec 2025 to 22 Oct 2024.
- 23 Dec 2019 Planned primary completion date changed from 15 Dec 2020 to 22 Oct 2020.
- 23 Dec 2019 Status changed from recruiting to active, no longer recruiting.